LIPELLA PHARMACEUTICALS INC. (LIPO)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Lipella Pharmaceuticals Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 11, 2026 | 0.0006 | 0.0006 | 0.0006 | 0.0006 | 43,343 |
| Nov 4, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 645 |
| Oct 28, 2026 | 0.0006 | 0.0006 | 0.0006 | 0.0006 | 353 |
| Oct 26, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 1,682 |
| Oct 23, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 915 |
| Oct 20, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 310 |
| Oct 16, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 400 |
| Oct 12, 2026 | 0.0006 | 0.0006 | 0.0006 | 0.0006 | 236 |
| Oct 9, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 300 |
| Oct 7, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 2,894 |
| Oct 2, 2026 | 0.0005 | 0.0005 | 0.0005 | 0.0005 | 594 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| See remarks below. | Other | 125.8K | -- | Apr 3, 2025 | |
| See remarks below. | Other | 4.1K | -- | Apr 3, 2025 | |
| See remarks below. | Other | 28.9K | -- | Apr 3, 2025 | |
| See remarks below. | Other | 537.0K | -- | Apr 3, 2025 | |
| See remarks below. | Other | 10.3K | -- | Mar 13, 2025 | |
| See remarks below. | Other | 4.1K | -- | Mar 13, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Jonathan H. Kaufman · may incl. warrants· filed Apr 2025 | 212.3K | 4.6% | 13D |
Michael B. Chancellor · may incl. warrants· filed Apr 2025 | 209.6K | 4.5% | 13D |
Leaf Huang · may incl. warrants· filed May 2025 | 69.4K | 1.5% | 13G |
SABBY MANAGEMENT, LLC · may incl. warrants· filed Jan 2025 | 60.3K | 1.3% | 13G |
Michele Gruber · may incl. warrants· stale · filed Nov 2024 | 5.9K | 0.1% | 13G |
Insiders
- Kaufman Jonathan HSee remarks below.
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies.
The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications.
Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis.
Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
7.88K
60d Avg
3.81K
90d Avg
3.88K
Signal8's dilution snapshot of LIPO as of Sep 30, 2025 records an effective S-3 shelf registration (effective Apr 3, 2025), an at-the-market sales agreement dated Apr 4, 2025, 7 outstanding warrant series and a PIPE closed Mar 17, 2025, from SEC filings. Lipella Pharmaceuticals Inc. (OTC: LIPO) traded at $0.0006 on Nov 11, 2026. 52-week range: $0.0002 to $0.5420. The company is in the Healthcare sector (Biotechnology).